Integrase-Deficient Lentiviral Vector as a Platform for Efficient CRISPR/Cas9-Mediated Gene Editing for Mucopolysaccharidosis IVA
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146616 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Fnu Nidhi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Nemours Children's Health, Wilmington, DE 19803, USA. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, Lentivirus, Mucopolysaccharidosis IV. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, A Cure for Robert, Inc., Morquio Foundations (A Cure for Robert, Inc., Angelo R. Cali & Mary V. Cali Family Foundation, The Bennett Foundation), and Nemours Funds.
Abstract (Originalsprache)
Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disorder causing systemic skeletal dysplasia due to a deficiency of N-acetyl-galactosamine-6-sulfate sulfatase (GALNS) enzyme activity, leading to the impaired degradation and accumulation of glycosaminoglycans (GAGs), keratan sulfate (KS) and chondroitin-6-sulfate. While treatments such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) are available, they have significant limitations regarding efficacy in skeletal tissues and long-term safety, highlighting the need for more effective therapies. We evaluated a novel gene therapy approach using a dual Integrase-deficient lentiviral vector (IDLV) to deliver an expression cassette that includes human GALNS cDNA and Cas9 sgRNA, targeting the upstream region of the mouse Galns initial codon. This approach leverages the endogenous promoter to drive transgene expression. We assessed in vitro transduction, editing, and functional correction in NIH3T3 and MPS IVA mouse fibroblasts. In vivo efficacy was successfully evaluated via the facial vein injection in MPS IVA newborn mice. In vitro, this IDLV platform demonstrated supraphysiological GALNS activity in cell lysate, resulting in the normalization of KS levels. In vivo direct IDLV platform in newborn MPS IVA mice led to sustained plasma GALNS activity, reduced plasma KS, and favorable biodistribution. Partial correction of heart and bone pathology was observed, with no vector toxicity and minimal antibody responses. This dual IDLV-CRISPR/Cas9 approach effectively mediated targeted GALNS knock-in, yielding sustained enzyme activity, reduced KS storage, and partial pathological amelioration in MPS IVA mice. In conclusion, IDLVs represent an efficient, safe platform for delivering the CRISPR/Cas9 gene editing system for MPS IVA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nemours Children's Health, Wilmington, DE 19803, USA.
- Faculty of Arts and Sciences, University of Delaware, Newark, DE 19716, USA.
- Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1193, Japan.
- Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA.
ORCID-Profile: Fnu Nidhi, Shunji Tomatsu
Förderung
- NIH HHS
- A Cure for Robert, Inc.
- Morquio Foundations (A Cure for Robert, Inc., Angelo R. Cali & Mary V. Cali Family Foundation, The Bennett Foundation), and Nemours Funds
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Zitieren
APA
Nidhi, F., & Tomatsu, S. (2025). Integrase-Deficient Lentiviral Vector as a Platform for Efficient CRISPR/Cas9-Mediated Gene Editing for Mucopolysaccharidosis IVA. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146616
Vancouver
Nidhi F, Tomatsu S. Integrase-Deficient Lentiviral Vector as a Platform for Efficient CRISPR/Cas9-Mediated Gene Editing for Mucopolysaccharidosis IVA. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146616
BibTeX
@article{Nidhi2025,
author = {Nidhi, Fnu and Tomatsu, Shunji},
title = {Integrase-Deficient Lentiviral Vector as a Platform for Efficient CRISPR/Cas9-Mediated Gene Editing for Mucopolysaccharidosis IVA},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146616}
}
EUVIMED